Featured Content

Newsletters and Deep Dive
digital magazine

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content

R&D
2nd Peptide-Based Therapeutics Summit banner
Partner Content

2nd Peptide-Based Therapeutics Summit

With Merck’s oral PCSK9 inhibitor demonstrating strong phase 3 trial results, J&J’s IL23R antagonist peptide continuing its phase 3 journey, and Chugai advancing peptides into the intracellular